Drug Profile
Research programme: anticancer therapeutics - Aptanomics/Nanosyn
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Aptanomics; Nanosyn
- Class Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 06 Nov 2006 This programme is still in active development